Sample Submission Guidelines
Why cfDNA Methylation Sequencing Requires a Different Approach
Our cell-free DNA (cfDNA) methylation sequencing platform offers high-sensitivity, high-resolution profiling designed specifically for oncology, prenatal testing, and organ transplant monitoring. Because cfDNA is highly fragmented and low-abundance, selecting the right methodology is critical.
Unlike genomic DNA extracted from tissue or cells, cfDNA circulates in blood plasma as short, double-stranded fragments — predominantly at mononucleosomal length. This fragility means that a methylation workflow optimized for intact gDNA can fail outright on cfDNA: harsh chemical conversion steps that are tolerable for microgram-scale tissue DNA can destroy the majority of an already-scarce plasma sample. At the same time, white blood cell lysis during sample handling can introduce contaminating genomic DNA that dilutes the true cfDNA methylation signal.
We address both challenges directly. Our platform offers three complementary sequencing methodologies — each with a different resolution, genomic coverage, and DNA damage profile — so that the method matches the sample, not the other way around. Combined with strict pre-analytical sample QC and a validated, Bismark-driven bioinformatics pipeline, this gives researchers a complete path from plasma tube to biological insight.
Sequencing Methodologies
We offer three primary workflows tailored to different sample inputs, target depths, and budget requirements.
Whole-Genome Bisulfite Sequencing (WGBS): The traditional gold standard for comprehensive, base-resolution profiling across the entire genome.
Enzymatic Methyl-Seq (EM-Seq): A non-destructive alternative to bisulfite treatment. It uses enzymatic conversion to minimize DNA damage and maximize library complexity. Learn more about our EM-Seq service.
Methylated DNA Immunoprecipitation Sequencing (MeDIP-Seq): An affinity-based method that captures methylated fragments. This provides an enrichment-based, cost-effective profile without base-level resolution. See our dedicated MeDIP sequencing page for protocol details.
| Method | Resolution | Genomic Coverage | DNA Damage | Input Requirement | Key Advantage | Key Disadvantage |
|---|---|---|---|---|---|---|
| WGBS | Base level | Global (>90% of CpGs) | Severe | High (≥10 ng) | True un-biased global profile | Destroys up to 90% of cfDNA |
| EM-Seq | Base level | Global (>90% of CpGs) | Minimal | Low (1–10 ng) | High mapping efficiency; intact fragments | Higher reagent costs |
| MeDIP-Seq | Regional (100–300 bp) | Methyl-rich zones | None | Medium (≥10 ng) | Highly cost-effective for large cohorts | Biased toward high-density CpG islands |
| Target-BS / Target-Seq | Base level | Targeted Panel (e.g., 10k–4M custom/pre-designed CpGs) | Variable (Severe if Bisulfite; Minimal if EM-Seq) | Low (1–10 ng) | Ultra-high sequencing depth (>500×) at low cost | Requires upfront panel/probe design |
For a side-by-side breakdown of CpG density preferences and resolution trade-offs, see our guide on comparing MeDIP-seq, RRBS, and WGBS.
Service Workflow
From plasma collection to publication-ready epigenetic insight — our pipeline is built specifically around cfDNA's fragility and low abundance.
Step 1 — Blood Collection & Plasma Isolation: Blood is collected in specialized cell-stabilizing tubes (e.g., Streck Cell-Free DNA BCT) or standard EDTA tubes, with plasma separated within 2 hours via double centrifugation to minimize white blood cell lysis and gDNA contamination.
Step 2 — cfDNA Extraction & QC: Purified cfDNA is quantified and assessed for fragment size distribution (target main peak 160–170 bp) and high-molecular-weight contamination (<10% of total DNA >1000 bp) before proceeding to library preparation.
Step 3 — Library Preparation: Depending on the selected methodology (WGBS, EM-Seq, or MeDIP-Seq), libraries are constructed using protocols optimized for low-input, fragmented cfDNA — preserving as much library complexity as the chosen chemistry allows.
Step 4 — Sequencing: Libraries are sequenced on next-generation sequencing platforms at depth appropriate to the chosen method, with spiked-in unmethylated Lambda DNA controls included for conversion efficiency monitoring.
Step 5 — Bioinformatics Analysis & Reporting: Raw reads are processed through our automated pipeline — pre-processing and QC, alignment, methylation extraction, and downstream analytics — culminating in a full data report covering methylation calls, DMRs, and where applicable, tissue-of-origin deconvolution.
Key Applications
cfDNA methylation sequencing supports research across non-invasive disease monitoring, prenatal screening, and post-transplant surveillance.
Oncology Biomarker Discovery & Early Detection
Tumor-derived cfDNA carries cancer-specific methylation signatures that often emerge before genetic mutations during carcinogenesis, making methylation profiling a sensitive complement to mutation-based liquid biopsy approaches. See our overview of cfDNA as a biomarker in precision oncology.
Prenatal Testing Research
Cell-free fetal DNA circulating in maternal plasma carries placenta-specific methylation patterns that can inform non-invasive prenatal screening research, leveraging the same low-input workflows developed for oncology applications.
Organ Transplant Monitoring
Donor-derived cfDNA released during graft injury carries tissue-specific methylation marks that can support non-invasive monitoring research for transplant rejection — complementing donor-derived cfDNA fraction quantification with epigenetic tissue-of-origin information. Our guide to ctDNA vs. cfDNA outlines the distinctions relevant to interpreting these signals.
Demo Results
Representative quality control outputs from our cfDNA methylation sequencing pipeline.
cfDNA fragment size distribution confirming a main peak within the target 160–170 bp range, consistent with mononucleosomal fragmentation and minimal genomic DNA contamination.
Conversion efficiency QC using spiked-in unmethylated Lambda DNA, confirming conversion rates exceeding the 99.5% target threshold across libraries.
Sample Requirements
cfDNA is highly sensitive to pre-analytical handling. Adhering to these strict sample parameters ensures optimal library yields and minimizes contamination from genomic DNA (gDNA) caused by white blood cell lysis.
- Blood Collection: Use specialized cell-stabilizing tubes (e.g., Streck Cell-Free DNA BCT) or collect in EDTA tubes, spinning down within 2 hours.
- Plasma Volume: Submit a minimum of 2–4 mL of double-centrifuged plasma (1600 × g followed by 16,000 × g).
- DNA Quantity: A minimum of 10 ng of purified cfDNA is recommended (1–5 ng is acceptable for EM-Seq).
- DNA Quality: Main peak must reside between 160–170 bp (representing mono-nucleosomal fragments) when verified via Agilent Bioanalyzer or TapeStation.
- Contamination Limit: High molecular weight peaks (>1000 bp) must constitute <10% of total DNA to ensure gDNA contamination does not dilute the cfDNA signal.
Bioinformatics Analysis & Deliverables
Our automated bioinformatics pipeline processes raw sequencing reads into biological insights using optimized, state-of-the-art tools.
Step 1 — Pre-processing & Quality Control: FastQC assesses raw data quality scores, adapter contamination, and base composition. Trimmomatic/Cutadapt trims low-quality bases (Q < 20) and removes sequencing adapters. For WGBS/EM-Seq, specific artificial C-to-T bias at the ends of reads (dark cycles) must be trimmed.
Step 2 — Alignment & Reference Mapping: Bismark/BWA-Meth maps converted reads to a specialized, computationally bisulfite-converted reference genome (e.g., hg38). PCR duplicates are removed using alignment start/end coordinates to ensure accurate quantification.
Step 3 — Methylation Extraction: Bismark Methylation Extractor extracts methylation status specifically for CpG, CHG, and CHH contexts. Conversion rate is calculated by quantifying the methylation rate of spiked-in unmethylated Lambda DNA (>99.5% target).
Step 4 — Downstream Advanced Analytics: Differentially Methylated Regions (DMRs) are identified using packages like DSS or methylKit. Deconvolution applies machine learning algorithms against reference atlases to determine tissue-of-origin or tumor fraction. Fragmentomics integrated analysis combines methylation signals with cfDNA size-profiling to enhance diagnostic accuracy.
Our expanded portfolio introduces a fully integrated, end-to-end research framework for cfDNA methylation analysis. By implementing low-input EM-Seq workflows, enforcing strict fragment-size quality controls, and leveraging a Bismark-driven analysis pipeline, we deliver high-resolution epigenetic insights from standard liquid biopsy samples.
References
- Liu J, Dai L, Wang Q, et al. Multimodal analysis of cfDNA methylomes for early detecting esophageal squamous cell carcinoma and precancerous lesions. Nat Commun. 2024;15:3700. https://doi.org/10.1038/s41467-024-47886-1
- Vaisvila R, Ponnaluri VKC, Sun Z, et al. Enzymatic methyl sequencing detects DNA methylation at single-base resolution from picograms of DNA. Genome Res. 2021;31(7):1280–1289. https://doi.org/10.1101/gr.266551.120
- Lo YMD, Han DSC, Jiang P, Chiu RWK. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science. 2021;372(6538):eaaw3616. https://doi.org/10.1126/science.aaw3616
For Research Use Only. Not for use in diagnostic or clinical procedures.
Demo Results
cfDNA fragment size distribution confirming a main peak within the target 160–170 bp range, consistent with mononucleosomal fragmentation and minimal genomic DNA contamination.
Conversion efficiency QC using spiked-in unmethylated Lambda DNA, confirming conversion rates exceeding the 99.5% target threshold across libraries.
cfDNA Methylation Sequencing FAQs
1. Which cfDNA methylation method should I choose for my sample type?
The choice depends primarily on your available DNA quantity and required resolution. If you have ≥10 ng of cfDNA and need unbiased, base-level resolution across the genome, WGBS is the traditional gold standard. If your input is limited to 1–10 ng or you want to preserve maximum library complexity, EM-Seq's enzymatic conversion avoids the DNA damage associated with bisulfite treatment. If you are working with large cohorts and cost-effectiveness matters more than single-base resolution, MeDIP-Seq's affinity-based enrichment of methylated fragments offers a practical, non-destructive alternative. For projects focused on a defined set of regions, Target-BS/Target-Seq panels deliver ultra-high depth at low per-sample cost, though they require upfront panel design.
2. How do I prevent gDNA contamination in my cfDNA sample?
Contamination most commonly arises from white blood cell lysis during blood handling. Using specialized cell-stabilizing collection tubes (e.g., Streck Cell-Free DNA BCT) or processing standard EDTA tubes within 2 hours via double centrifugation (1600 × g followed by 16,000 × g) substantially reduces this risk. We also verify every submitted sample against our contamination limit — high molecular weight DNA peaks (>1000 bp) must constitute less than 10% of total DNA — before proceeding to library preparation.
3. What is the minimum cfDNA input required?
A minimum of 10 ng of purified cfDNA is recommended for WGBS and MeDIP-Seq. EM-Seq accommodates lower input, with 1–5 ng acceptable due to its non-destructive enzymatic conversion chemistry. Target-BS/Target-Seq panels similarly support 1–10 ng input ranges depending on the conversion chemistry selected for the targeted workflow.
4. Can EM-Seq replace WGBS entirely for cfDNA?
EM-Seq offers clear advantages for low-input, fragmented cfDNA — minimal DNA damage and intact fragment preservation translate to higher mapping efficiency from the same starting material. However, WGBS remains valuable when an unbiased, well-established global profile is the primary goal and sufficient input DNA is available. Many research programs use EM-Seq as the default for routine cfDNA profiling while reserving WGBS for specific validation or cross-comparison purposes.
5. What does tissue-of-origin deconvolution actually tell me?
Tissue-of-origin deconvolution applies machine learning algorithms to compare your sample's methylation profile against reference methylation atlases built from known cell and tissue types. The output estimates the proportional contribution of different tissues to your cfDNA pool — for example, distinguishing tumor-derived fractions from normal hematopoietic background, or identifying graft-derived signal in transplant monitoring research. This analysis is most informative when combined with fragmentomics data, which is why our downstream analytics integrate both signal types.
cfDNA Methylation Sequencing Case Studies
Published Research Highlight
Multimodal Analysis of cfDNA Methylomes for Early Detecting Esophageal Squamous Cell Carcinoma and Precancerous Lesions
Journal: Nature Communications
Published: May 2, 2024
DOI: 10.1038/s41467-024-47886-1
Background
Esophageal squamous cell carcinoma (ESCC) is most commonly detected at a late stage, which limits survival and treatment options. Detecting early-stage ESCC and precancerous lesions non-invasively has remained an unmet need, and methylation signatures in cfDNA — which often emerge before genetic alterations during carcinogenesis — represent a promising avenue for early detection research.
Materials & Methods
Sample Preparation
- 460 cfDNA samples from patients with non-metastatic ESCC or precancerous lesions and matched healthy controls
- Paired WGBS and whole-genome sequencing (WGS) data from primary tumors and matched adjacent non-neoplastic tissues of 155 ESCC patients used to identify cancer-derived markers
Sequencing
- Whole-genome bisulfite sequencing (WGBS) on all 460 cfDNA samples
- cfDNA methylation, copy number variant (CNV), and fragmentation features extracted from the same WGBS data
Data Analysis
- Expanded multimodal analysis (EMMA) framework combining methylation, CNV, and fragmentation markers
- Machine learning-based classification with validation cohort testing
Results
- cfDNA Methylation Markers Are the Earliest and Most Sensitive Signal
- cfDNA methylation markers were detectable in 70% of ESCCs and 50% of precancerous lesions, and were associated with molecular subtypes and tumor microenvironments (Fig. 1).
- CNVs and fragmentation features showed high specificity but were linked predominantly to late-stage disease, underscoring methylation's advantage for early detection.
- The EMMA Framework Significantly Improves Detection Rates
- Combining methylation, CNV, and fragmentation markers within the EMMA framework increased AUCs from 0.90 to 0.99 compared with single-modality analysis.
- EMMA detected 87% of ESCCs and 62% of precancerous lesions with greater than 95% specificity in validation cohorts.
Fig. 1 — Study design and patient enrollment for the EMMA (expanded multimodal analysis) framework, combining cfDNA methylation, CNV, and fragmentation markers from whole-genome bisulfite sequencing data. (Liu J et al., Nat Commun, 2024)
Conclusion
This study demonstrates that cfDNA methylation markers, derived through whole-genome bisulfite sequencing, provide the earliest and most sensitive signal for detecting both early-stage ESCC and precancerous lesions — outperforming CNV and fragmentation-only approaches at early disease stages. The multimodal EMMA framework illustrates the broader research value of comprehensive cfDNA methylome profiling: combining methylation calls with complementary genomic features substantially improves detection performance over any single data type alone.
Reference
- Liu J, Dai L, Wang Q, et al. Multimodal analysis of cfDNA methylomes for early detecting esophageal squamous cell carcinoma and precancerous lesions. Nat Commun. 2024;15:3700. https://doi.org/10.1038/s41467-024-47886-1
